BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment
9.12.2024 03:05:00 CET | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions.
2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development
Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies further demonstrated no adverse local effects, highlighting the viability of the sublingual delivery approach.
Advancements in Manufacturing: BioNxt successfully transferred the BNT23001 production process to its GMP-certified manufacturing partner, Gen-Plus GmbH & Co KG in Munich (Germany), ensuring readiness for clinical batch production. This milestone supports the Company's plan to initiate clinical trials in 2025 with reliable, high-quality product supply.
Strengthened Intellectual Property Position: A favorable International Preliminary Report on Patentability (IPRP) confirmed BNT23001's novelty, inventive step, and industrial applicability, underscoring its unique value in MS treatment. The Company has initiated patent nationalization in major jurisdictions, including Europe, the United States, and Canada, with patent grants anticipated in several regions by mid-2025.
2025 Roadmap: Advancing BNT23001 into Clinical Trials
Manufacturing Clinical Batches: BioNxt will complete GMP manufacturing and Qualified Person (QP) release of clinical trial batches in the second quarter of 2025. This step is critical for the successful initiation of human studies.
Regulatory Filings and Approvals: The Company plans to submit the Investigational Medicinal Product Dossier (IMPD) to European regulatory authorities by mid-2025, paving the way for clinical trial approval. These regulatory submissions will include data from preclinical studies and stability assessments conducted at the manufacturing site.
Clinical Study to Validate Performance: BioNxt aims to launch a pilot clinical study in the latter half of 2025. This trial will compare the efficacy, bioavailability, and safety of BNT23001 to Mavenclad®, the originator tablet product, positioning the thin-film formulation as a patient-friendly alternative.
Ongoing Patent Protection: In addition to continuing the patent nationalization process, BioNxt expects granted patents in key regions to strengthen its intellectual property portfolio and provide competitive advantages as the product moves toward commercialization.
BNT23001: Advancing Toward Clinical Validation for MS Treatment
BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:
• Convenience: Easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles.
• Rapid Absorption: Direct delivery through the sublingual mucosa for faster therapeutic action.
• Improved Compliance: A patient-friendly alternative designed to enhance adherence to prescribed regimens.
By delivering these advantages, BNT23001 aligns with BioNxt's mission to improve outcomes for patients living with chronic diseases like MS.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 780-818-6422
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BNT23001, as well as projected milestones for 2025. These statements are based on current expectations and assumptions but involve risks and uncertainties that could cause actual results to differ materially. These risks include clinical trial outcomes, regulatory delays, manufacturing challenges, intellectual property issues, market competition, and changes in laws or market conditions. The Company undertakes no obligation to update or revise forward-looking statements, except as required by law. For more information, refer to the "Risk Factors" section of the Company's filings at www.sedarplus.ca.
Trademarks: Mavenclad® is a registered trademark of EMD Serono, Inc. BioNxt Solutions Inc. is not affiliated with or endorsed by EMD Serono.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Aehr Test Systems Appoints Former Meta Infrastructure Executive Vijay Rao to Board of Directors29.10.2026 12:30:00 CET | Press release
FREMONT, CA / ACCESS Newswire / October 29, 2026 / Aehr Test Systems (NASDAQ:AEHR), a leading provider of test and burn-in solutions for semiconductor devices used in artificial intelligence (AI), silicon photonics, data center, automotive, and industrial applications, today announced the appointment of Vijay Rao to its Board of Directors, effective October 28, 2026. Rao brings 30 years of technology industry experience, including more than 13 years at Meta, where he most recently served as Vice President of Infrastructure. His experience spans infrastructure strategy, AI computing, and semiconductor technologies in hyperscale, enterprise, and startup environments. "Vijay brings deep expertise in infrastructure requirements of hyperscale data centers, including the integration of AI accelerators, high-performance memory, and optical networking," said Gayn Erickson, President and Chief Executive Officer of Aehr Test Systems. "He understands firsthand how semiconductor quality and reliab
U.S. Polo Assn. Executes Early on Europe's Digital Product Passport Mandate29.10.2026 12:00:00 CET | Press release
WEST PALM BEACH, FL / ACCESS Newswire / October 29, 2026 / U.S. Polo Assn.®, the official sports brand of the United States Polo Association (USPA), with a multi-billion-dollar global footprint and distribution in more than 190 countries through some 1,200 U.S. Polo Assn. mono-brand retail stores, numerous branded websites and thousands of other points of distribution worldwide, today announced the brand's early activation of Digital Product Passports (DPPs) across product categories sold into the European Union (EU). As Europe prepares to launch the Digital Product Passport Registry, U.S. Polo Assn. has taken a proactive approach by preparing to deploy DPPs across all products sold into the EU well ahead of the mandatory compliance deadline expected in 2028 or 2029. The global sports brand has already mapped product information for millions of products, creating a scalable framework that will enhance product transparency and support compliance readiness throughout its European operati
LiberNovo Previews Treat Yourself Halloween Flash Sale Across Europe29.10.2026 08:40:00 CET | Press release
HONG KONG, HK / ACCESS Newswire / October 29, 2026 / LiberNovo is bringing Halloween treats to the desk with its Treat Yourself Halloween Flash Sale, opening October 29 across the European Union and United Kingdom. The event pairs savings of up to 40% on selected Maxis and LiberNovo Omni Pro configurations with limited seasonal gifts for qualifying early shoppers. Spooky extras for your desk Limited Halloween-themed gift packs are available to the first 300 eligible customers in the European Union and the first 100 in the United Kingdom, on a first-come, first-served basis while supplies last. Gift contents, qualifying purchases and availability follow the terms on each regional campaign page. More room for Big and Tall users Maxis is designed around larger frames, with a wider seat and 52 cm seat depth for greater thigh support and room to shift naturally. Maxis Manual provides adjustment by hand. Maxis Electric adds motorised lumbar adjustment and OmniStretch guided back stretching.
IAVI Awarded $36 Million From BARDA for Bundibugyo Virus Vaccine Development28.10.2026 16:50:00 CET | Press release
NEW YORK, NY, SINGAPORE, SG INCHEON, SOUTH KOREA, AND DESSAU-ROSSLAU, DE / ACCESS Newswire / October 28, 2026 / Today IAVI, a global nonprofit biomedical research organization, together with partners Hilleman Laboratories, SK bioscience, and IDT Biologika announced that IAVI has been awarded US $36 million of a contract valued up to US $99 million from the Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, to advance development, manufacturing, and clinical evaluation of its one-dose vaccine candidate against Bundibugyo virus (BDBV), the cause of the ongoing Ebola epidemic in the Democratic Republic of the Congo (DRC). The award supports manufacturing of vaccine doses for clinical evaluation and outbreak response, clinical and regulatory activities including a Phase 1 trial, and options for expanded manufacturing to support future preparedness needs, as
GA-ASI and Saab Perform Advanced AEW Flight Testing on Uncrewed MQ-9B28.10.2026 16:00:00 CET | Press release
SAN DIEGO, CA / ACCESS Newswire / October 28, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) has partnered with Saab to perform advanced flight testing of an Airborne Early Warning (AEW) system on an Uncrewed Aircraft System (UAS). The flight testing was conducted over the past few months using a GA-ASI-produced MQ-9B carrying a Saab LoyalEye radar operating from GA-ASI's Desert Horizon flight operations facility in Southern California. The flight test demonstrated simultaneous tracking of several airborne and maritime targets at long ranges. The airborne targets tracked included multiple instrumented red fighter jets and several commercial aircraft. MQ-9B is GA-ASI's flagship UAS, offering unmatched endurance, type certification and all-weather performance. GA-ASI is discussing unmanned AEW capabilities on MQ-9B with several customers. "This has been one of the most highly anticipated flight tests we have performed," said GA-ASI President David R. Alexander. "The level of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom